Want to join the conversation?
$PFE reported that US FDA's Arthritis Advisory Committee has approved biosimilar infliximab across all eligible indications by a vote of 21 to 3. $PFE holds exclusive US commercialization rights for Celltrion's nfliximab. FDA is considering infliximab for all indications, including treatment of rheumatoid arthritis and adult ulcerative colitis.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th